UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

The lancet oncology, 2022-03, Vol.23 (3), p.362-373

2022

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2022-09, Vol.23 (9), p.1133-1144

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2019-03, Vol.380 (12), p.1116-1127

2019

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1029-1039

2021

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

Cancer Immunology, Immunotherapy, 2020-06, Vol.69 (6), p.983-988

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS769-TPS769

2020

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Future oncology (London, England), 2021-09, Vol.17 (25), p.3291-3299

2021

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.546-546

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.19-19

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.129-129

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4513-4513

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT106: Primary tumor response in T1aN0M0 renal cell carcinoma patients ineligible for surgery and treated with nivolumab and ipilimumab: Results from phase 2 pilot study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT106-CT106

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4500-4500

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract A1: Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab

Cancer immunology research, 2020-03, Vol.8 (3_Supplement), p.A1-A1

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.327-327

2021

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5069-5069

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(11)
Oncology
(10)
Male
(9)
Adult
(6)
Carcinoma, Renal Cell - Drug Therapy
(6)
Female
(6)
Metastases
(6)
Metastasis
(6)
Middle Aged
(6)
Pembrolizumab
(6)
Immunotherapy
(5)
Kidney Neoplasms - Drug Therapy
(5)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Carcinoma, Renal Cell - Pathology
(4)
Clear Cell-Type Renal Cell Carcinoma
(4)
Follow-Up Studies
(4)
Kidney Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study

Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

Abstract CT106: Primary tumor response in T1aN0M0 renal cell carcinoma patients ineligible for surgery and treated with nivolumab and ipilimumab: Results from phase 2 pilot study

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Abstract A1: Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Suchergebnisse filtern